IMC-C103C

IMC-C103C is a novel bispecific T-cell redirecting biologic developed using Immunocore’s proprietary ImmTAC (Immune mobilizing monoclonal TCRs Against Cancer) technology platform. It consists of an affinity-enhanced soluble T cell receptor (TCR) that specifically targets the cancer testis antigen MAGE-A4 presented by HLA-A*02:01 on tumor cells and is fused to an anti-CD3 single-chain variable fragment (scFv). Upon intravenous administration, the TCR moiety binds to MAGE-A4 on tumor cells while the anti-CD3 scFv engages CD3-expressing T lymphocytes. This cross-links tumor cells and T lymphocytes, resulting in cytotoxic T lymphocyte-mediated killing of MAGE-A4-expressing cancer cells. The drug is being developed primarily for solid tumors expressing MAGE-A4 and has shown increased intratumoral T cell infiltration in early clinical studies. IMC-C103C is co-developed by Immunocore and Genentech/Roche[1][2][3][4][5][6][8].

Other names

IMC-C103CIMC-C-103CIMC-C 103CMAGE-A4 ImmTACMAGE-A-4 ImmTACMAGE-A 4 ImmTACRG-6290RG6290RG 6290